Cargando…

Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis

BACKGROUND: Receptor selectivity of sodium-glucose cotransporter-2 inhibitors (SGLT2i) varies greatly between agents. The overall improvement of cardiovascular (CV) outcomes in heart failure (HF) patients varies between trials. We, therefore, evaluated the comparative efficacy of individual SGLT2i a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Täger, Tobias, Frankenstein, Lutz, Atar, Dan, Agewall, Stefan, Frey, Norbert, Grundtvig, Morten, Clark, Andrew L., Cleland, John G. F., Fröhlich, Hanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971161/ https://www.ncbi.nlm.nih.gov/pubmed/34498169 http://dx.doi.org/10.1007/s00392-021-01913-z

Ejemplares similares

Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
por: Täger, Tobias, et al.
Publicado: (2020)

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
por: Fröhlich, Hanna, et al.
Publicado: (2022)

N‐terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure
por: Schnorbach, Johannes, et al.
Publicado: (2019)

Peritoneal ultrafiltration in end-stage chronic heart failure
por: Fröhlich, Hanna, et al.
Publicado: (2015)

Prognostic value of changes in high-sensitivity cardiac troponin T beyond biological variation in stable outpatients with cardiovascular disease: a validation study
por: Biener, Moritz, et al.
Publicado: (2021)

Biological variation of the cardiac index in patients with stable chronic heart failure: inert gas rebreathing compared with impedance cardiography
por: Täger, Tobias, et al.
Publicado: (2015)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure
por: Stubnova, Viera, et al.
Publicado: (2019)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Impact of the introduction of percutaneous edge-to-edge mitral valve reconstruction on clinical practice in Germany compared to surgical valve repair
por: Frankenstein, Lutz, et al.
Publicado: (2020)

Regenerative heart failure therapy headed for optimization
por: Terzic, Andre, et al.
Publicado: (2014)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review
por: Delgado, Elías, et al.
Publicado: (2022)

Prognostic utility of B-type natriuretic peptides in patients with heart failure and renal dysfunction
por: Waldum, Bård, et al.
Publicado: (2013)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

6 min walk test is a strong independent predictor of death in outpatients with heart failure
por: Grundtvig, Morten, et al.
Publicado: (2020)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

The need for dedicated advanced heart failure units to optimize heart failure care: impact of optimized advanced heart failure unit care on heart transplant outcome in high‐risk patients
por: Kreusser, Michael M., et al.
Publicado: (2018)

The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model
por: Ha, Chae-Myeong, et al.
Publicado: (2019)

Heading in Soccer: Does Kinematics of the Head‐Neck‐Torso Alignment Influence Head Acceleration?
por: Becker, Stephan, et al.
Publicado: (2021)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

Glaucomatous optic nerve head alterations in patients with chronic heart failure
por: Meira-Freitas, Daniel, et al.
Publicado: (2012)

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
por: Oh, Chang-Myung, et al.
Publicado: (2019)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
por: Voorrips, Suzanne N., et al.
Publicado: (2022)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)

Benefits of Low-Dose CT Scan of Head for Patients With Intracranial Hemorrhage
por: Wu, Dan, et al.
Publicado: (2020)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers
por: Ettl, Tobias, et al.
Publicado: (2022)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2022)

Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme
por: Gastelurrutia, Paloma, et al.
Publicado: (2016)

Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care
por: Packer, Milton
Publicado: (2020)

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
por: Lam, Carolyn S. P., et al.
Publicado: (2019)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
por: Pabel, Steffen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4b157c98dsd5nhq1ha8m6eh3i8